Ziritaxestat

Description: Ziritaxestat (GLPG1690), an autotaxin inhibitor, currently being evaluated in an exploratory phase 2 study in idiopathic pulmonary fibrosis patients. Target: PDE. Smiles: CCc1nc2c(C)cc(cn2c1CNc1nc(c(s1)C#N)-c1ccc(F)cc1)N1CCN(CC(=O)N2CC(O)C2)CC1. References: Desroy N., et al. Discovery of 2-[[2-Ethyl-6-[4-[2-(3-hydroxyazetidin-1-yl)-2-oxoethyl]piperazin-1-yl]-8-methylimidazo[1,2-a]pyridin-3-yl]methylamino]-4-(4-fluorophenyl)thiazole-5-carbonitrile (GLPG1690), a First-in-Class Autotaxin Inhibitor Undergoing Clinicalal Evaluation for the Treatment of Idiopathic PulmoN/Ary Fibrosis. J Med Chem. 2017 May 11,60(9):3580-3590.